Evidence map›Paper›PMID 33550923›Full record

ArticleTechnology in cancer research & treatment

MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.

Xin-Bo Sun, Yong-Wei Chen, Qi-Sheng Yao, Xu-Hua Chen, Min He, Cong-Bo Chen, Yong Yang, Xiao-Xin Gong, Li Huang

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xin-Bo SunDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Yong-Wei ChenDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Qi-Sheng YaoDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.ORCID 0000-0002-2831-9780
Xu-Hua ChenDepartment of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Min HeDepartment of Gynaecology and Obstetrics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Cong-Bo ChenDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Yong YangDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Xiao-Xin GongDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Li HuangDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Hubei University of Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is a common malignant tumor with a high incidence. MicroRNAs (miRNAs) have been shown to be important post-transcriptional regulators during tumorigenesis. This study aimed to explore the effect of miR-144 on PCa proliferation and apoptosis. MATERIAL AND

methodsThe expression of miR-144 and EZH2 were examined in clinical PCa tissues. PCa cell line LNCAP and DU-145 was employed and transfected with miR-144 mimics or inhibitors. The correlation between miR-144 and EZH2 was verified by luciferase reporter assay. Cell viability, apoptosis and migratory capacity were detected by CCK-8, flow cytometry assay and wound healing assay. The protein level of EZH2, E-Cadherin, N-Cadherin and vimentin were analyzed by western blotting.

resultsmiR-144 was found to be negatively correlated to the expression of EZH2 in PCa tissues. Further studies identified EZH2 as a direct target of miR-144. Moreover, overexpression of miR-144 downregulated expression of EZH2, reduced cell viability and promoted cell apoptosis, while knockdown of miR-144 led to an inverse result. miR-144 also suppressed epithelial-mesenchymal transition level of PCa cells.

conclusionOur study indicated that miR-144 negatively regulate the expression of EZH2 in clinical specimens and in vitro. miR-144 can inhibit cell proliferation and induce cell apoptosis in PCa cells. Therefore, miR-144 has the potential to be used as a biomarker for predicting the progression of PCa.

Indexed as

Gene Expression Regulation, NeoplasticRNA Interference3' Untranslated RegionsAgedAged, 80 and overApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationEnhancer of Zeste Homolog 2 ProteinEpithelial-Mesenchymal TransitionHumansMaleMicroRNAsMiddle AgedNeoplasm Grading3' Untranslated RegionsBiomarkers, TumorEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMicroRNAsMIRN144 microRNA, humanapoptosisEMTezh2mir-144proliferationprostate cancer

Identifiers

PMID33550923
PMCPMC7876575
OpenAlexW3126197446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.